Analysts expect some biotech and pharma stocks, like Vir Biotechnology, to double in value, despite past share price declines and high volatility.
Vir Biotechnology's stock has shown resilience with a 14% increase from its 52-week low and support from institutional investors like BlackRock and Vanguard.
Collection
[
|
...
]